CSL Ltd
ASX:CSL
Relative Value
The Relative Value of one
CSL
stock under the Base Case scenario is
hidden
AUD.
Compared to the current market price of 141.03 AUD,
CSL Ltd
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
CSL Competitors Multiples
CSL Ltd Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| AU |
|
CSL Ltd
ASX:CSL
|
68B AUD | 3.1 | 34.5 | 11.4 | 14.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
388.4B USD | 6.4 | 92.8 | 15.3 | 21.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.4B USD | 5.4 | 25.6 | 14.7 | 14.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
179.9B USD | 6.1 | 21.2 | 13.2 | 16.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119.2B USD | 9.9 | 30.2 | 22.7 | 23.7 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.8B USD | 5.5 | 17.5 | 12.9 | 14.8 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
37.8B EUR | 10.6 | 34 | 36.8 | 37.6 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
41.5B USD | 11.2 | 132.4 | 73.8 | 82 |